Irreversible myeloperoxidase inhibitor mitiperstat and mitiperstat metabolites display immunogenicity in humans
Toxicological Sciences · 02.11.2026 · 209 (11)
DOI: 10.1093/toxsci/kfag140 ↗Kurz gefasst
Fachartikel in der Zeitschrift Toxicological Sciences, online erschienen am 27.10.2026. Verfasst von Lonnie I J MacDonald und 10 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacology and Therapeutics, University of Liverpool, Liverpool L69 3GE, United Kingdom. Hauptthemen laut MEDLINE: Peroxidase, Enzyme Inhibitors, T-Lymphocytes. Die Arbeit nennt 41 Literaturangaben. Gefördert von: University of Liverpool-AstraZeneca collaborative.
Abstract (Originalsprache)
Myeloperoxidase (MPO) dysregulation contributes to cardiovascular disease, making MPO a promising therapeutic target. Mitiperstat, an irreversible 2-thioxanthine MPO inhibitor in clinical development, has been linked to delayed-onset maculopapular rash. This study investigated whether mitiperstat and its metabolites (M7, M9, M10, M12) activate human T-cells in vitro. De novo T-cell responses from healthy donors were assessed using a dendritic cell: T-cell co-culture assay, and T-cell clones (TCCs) were characterized for compound specificity, phenotype, function, and cross-reactivity. Proliferation was measured by [3H]-thymidine incorporation, and cytokine/cytolytic molecule release (IFN-γ, IL-5, IL-13, granzyme-B) by ELISpot. Twenty-nine predominantly CD4+ TCCs were specific to mitiperstat, while forty-seven CD4+ and CD8+ TCCs responded to its metabolites. All drug-specific TCCs proliferated dose-dependently and secreted a heterogeneous Th1/Th2 cytokine and cytolytic profile. CD4+ and CD8+ TCC activation was attenuated by MHC-class II and MHC-class I blockade, respectively. Despite the irreversible on-target pharmacology of mitiperstat, nearly all responsive TCCs were activated via direct pharmacological interactions with proliferation occurring with drug or respective metabolite in the presence of glutaraldehyde-fixed antigen-presenting cells. In contrast, one TCC was activated with drug-pulsed antigen-presenting cells. TCCs showed high specificity for their cognate compounds with no cross-reactivity. These findings demonstrate the intrinsic immunogenicity of mitiperstat and its metabolites and establish a framework for assessing and comparing T-cell reactivity of future MPO-targeting therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmacology and Therapeutics, University of Liverpool, Liverpool L69 3GE, United Kingdom.
- Federal Institute of Biology, University Hospital of Toulouse, 31000, France.
- Safety Sciences, Clinical Pharmacology & Safety Sciences, AstraZeneca R&D, Cambridge CB2 0AA, United Kingdom.
- Cardiovascular, Renal and Metabolism, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, 431 83 Mölndal, Sweden.
ORCID-Profile: Joshua Gardner, Erik Michaëlsson, Xiaoli Meng, Dean J Naisbitt
Förderung
- University of Liverpool-AstraZeneca collaborative
Zitieren
APA
MacDonald, L. I. J., Martinez-Rivera, S., Wells, G., Gardner, J., Thomson, P., Whatling, C., Michaëlsson, E., Farrell, L., Meng, X., Betts, C. J., & Naisbitt, D. J. (2026). Irreversible myeloperoxidase inhibitor mitiperstat and mitiperstat metabolites display immunogenicity in humans. Toxicological Sciences, 209(11). https://doi.org/10.1093/toxsci/kfag140
Vancouver
MacDonald LIJ, Martinez-Rivera S, Wells G, Gardner J, Thomson P, Whatling C, et al. Irreversible myeloperoxidase inhibitor mitiperstat and mitiperstat metabolites display immunogenicity in humans. Toxicological Sciences. 2026;209(11). doi:10.1093/toxsci/kfag140
BibTeX
@article{MacDonald2026,
author = {MacDonald, Lonnie I J and Martinez-Rivera, Silvia and Wells, Georgia and Gardner, Joshua and Thomson, Paul and Whatling, Carl and Michaëlsson, Erik and Farrell, Liam and Meng, Xiaoli and Betts, Catherine J and Naisbitt, Dean J},
title = {Irreversible myeloperoxidase inhibitor mitiperstat and mitiperstat metabolites display immunogenicity in humans},
journal = {Toxicological Sciences},
year = {2026},
volume = {209},
number = {11},
doi = {10.1093/toxsci/kfag140}
}
EUVIMED